Business Context and Reporting Period
SeaStar Medical Holding Corp (ICU) filed a Form 8-K on August 1, 2025, reporting a material definitive agreement entered into on July 31, 2025. The company, incorporated in Delaware and headquartered in Denver, Colorado, is an emerging growth company.
Key Financial Metrics and Transaction Details
The filing details a registered direct offering and concurrent private placement with the following terms:
- Shares Issued: 4,960,544 shares of Common Stock.
- Warrants Issued: Warrants to purchase up to 4,960,544 shares of Common Stock at an exercise price of $0.762 per share.
- Offering Price: $0.887 per share and accompanying warrant.
- Expected Net Proceeds: Approximately $3.9 million after deducting placement agent fees and offering expenses.
- Placement Agent Fees: 7.0% cash fee, 1.0% management fee, $25,000 expense allowance, up to $50,000 legal reimbursement, and a $15,950 closing fee.
- Placement Agent Warrants: 347,238 warrants issued to H.C. Wainwright & Co., LLC with an exercise price of $1.1088 per share (125% of offering price), expiring July 31, 2030.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Use of Proceeds
The primary material change is the dilution of existing shareholders through the issuance of new equity and warrants. The company intends to use the net proceeds for general corporate purposes, including costs and expenses associated with being a public company. The transaction is expected to close on August 1, 2025.
Guidance, Outlook, and Restrictions
The filing does not contain forward-looking financial guidance or management commentary regarding future performance. However, it outlines significant contractual restrictions:
- Lock-up Period: The Company agreed not to issue or announce the issuance of Common Stock or convertible securities for 30 days after the closing date, subject to exceptions.
- Variable Rate Restriction: The Company agreed not to effect any variable rate transactions for six months following the closing date.
- Warrant Exercise Limitations: Holders cannot exercise warrants if doing so would result in beneficial ownership exceeding 4.99% or 9.99% of outstanding shares.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds received on August 1, 2025.
- Confirm the total number of shares outstanding post-closing to assess dilution impact.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific indemnification obligations and termination provisions.
- Monitor the filing of the registration statement for the resale of Common Warrant Shares and Placement Agent Warrant Shares, required within 30 days of July 31, 2025.
- Check subsequent filings for any updates on the use of proceeds or changes in the company's liquidity position.